Beam Therapeutics Inc. (BEAM)
Automate Your Wheel Strategy on BEAM
With Tiblio's Option Bot, you can configure your own wheel strategy including BEAM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BEAM
- Rev/Share 0.543
- Book/Share 9.4179
- PB 2.9614
- Debt/Equity 0.1567
- CurrentRatio 6.0175
- ROIC -0.4086
- MktCap 2830136188.0
- FreeCF/Share -3.4353
- PFCF -8.0319
- PE -6.8992
- Debt/Assets 0.1155
- DivYield 0
- ROE -0.4286
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BEAM | Jefferies | -- | Buy | -- | $41 | Oct. 9, 2025 |
| Upgrade | BEAM | BofA Securities | Neutral | Buy | -- | $42 | March 28, 2025 |
| Upgrade | BEAM | Scotiabank | Sector Perform | Sector Outperform | -- | $40 | March 10, 2025 |
| Upgrade | BEAM | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Jan. 29, 2025 |
| Initiation | BEAM | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Published: March 10, 2025 by: Benzinga
Sentiment: Positive
On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.
Read More
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Read More
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans …
Read More
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Read More
About Beam Therapeutics Inc. (BEAM)
- IPO Date 2020-02-06
- Website https://www.beamtx.com
- Industry Biotechnology
- CEO John Evans
- Employees 393